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All-trans retinoic acid (ATRA), a derivative of vitamin A, is an essential component in the treatment of acute promyelocytic
leukemia (APL). Though considered to be a relatively safe drug, use of ATRA can lead to several side eﬀects such as retinoic acid
syndrome and pseudotumor cerebri (PC). PC is a rare disorder characterized by neurologic and ocular signs and symptoms
of increased intracranial pressure, but with normal cerebrospinal ﬂuid composition and normal brain imaging. Most of the
previous studies suggest that PC, as a complication of ATRA therapy, occurs predominantly in the pediatric age group. Herein, we
report a rare case of ATRA-induced PC in a 38-year-old woman undergoing induction treatment for APL. Symptoms improved
with discontinuation of ATRA and treatment with acetazolamide. Concomitant administration of medications such as triazole
antifungals which inﬂuence the cytochrome P-450 system can exacerbate this potential complication of ATRA. In this paper, we
also review the current literature, provide a descriptive analysis of clinical features, and discuss the principles of management of
ATRA-induced PC.
1.Introduction
Acute promyelocytic leukemia (APL) is a distinct clinico-
pathologic disorder that accounts for 10% to 15% of cases of
acute myeloid leukemia (AML). The unique features of APL
have been well chronicled [1, 2] and include a characteristic
morphologic appearance [3]; a reciprocal translocation
between the long arm of chromosomes 15 and 17, leading to
fusion of promyelocytic leukemia (PML)-promoter gene to
the retinoic acid receptor (RAR)-α gene, which results in the
formation of PML-RAR-α fusion gene, younger age of onset,
and a severe coagulopathy with a high incidence of early
fatal hemorrhage [1, 2, 4–7]. White blood count (WBC) at
presentationhasbeenidentiﬁedasthesinglemostimportant
prognostic factor for clinical outcome [8, 9].
All-trans retinoic acid (ATRA), a derivative of vitamin
A, when combined with anthracycline-based chemotherapy
yields a complete remission (CR) rate in excess of 90% in
clinical trials involving patients with APL [9–11]. However,
ATRA has also been associated with several side eﬀects,
including skin problems (dryness, peeling, itching, and sun
sensitivity), reversible elevation in liver enzymes, abnormal
lipid levels, hypothyroidism, and headaches. Less commonly,
ATRA has been associated with cerebral and myocardial
infarction, corneal deposits secondary to hypercalcemia,
scrotal ulcerations, Sweet’s syndrome, Fournier’s gangrene,
APL diﬀerentiation syndrome, and pseudotumor cerebri
(PC) [5, 7, 9, 12–14]. PC is characterized by symptoms and
signs of increased intracranial pressure, including headache,
diplopia, and papilledema, with a normal cerebrospinal ﬂuid
(CSF) composition, and brain imaging ﬁndings [15–17].
(Table 1) Papilledema, though a common manifestation of
PC, is not an essential criterion for its diagnosis [16, 18].
The exact pathogenesis of ATRA-induced PC has not been
established [19, 20]. Several previous studies report, that PC
is a complication of ATRA therapy occurring predominantly
in pediatric patients usually within 2 weeks of initiation of
treatment [19].2 Case Reports in Oncological Medicine
Table 1: Modiﬁed Dandy criteria for diagnosis of pseudotumor cerebri [16].
(1) If symptoms and signs are present, they may only reﬂect those of generalized intracranial hypertension or papilledema.
The most common symptoms reﬂecting generalized intracranial hypertension are headache, pulsatile intracranial noises, and double
vision. Symptoms reﬂecting papilledema include transient visual obscurations and peripheral visual loss.
(2) Elevated intracranial pressure must be documented with the patient lying in the lateral decubitus position.
A lumbar CSF opening pressure greater than 250mm H2O is indicative of this disorder. Readings between 200mm and 250mm H2O are
nondiagnostic.
(3) CSF must be normal.
There must be no evidence of pleocytosis, cellular atypia, or hypoglycorrhachia, and CSF protein levels should be normal.
(4) There must be no evidence of hydrocephalus, mass, structural, or vascular lesion on MRI or contrast-enhanced CT for typical patients
and on an MRI and MR venography for atypical patients.
VST is rare in typical patients (i.e., an obese woman of childbearing age). Therefore, a CT is suﬃcient even though it cannot detect VST.
The incidence of VST and other vascular lesions increases signiﬁcantly in atypical patients. Consequently, an MRI or MR venography scan
is warranted given their heightened ability at detecting these diﬀerential disorders.
(5) No other cause of pseudotumor cerebri can be identiﬁed.
CSF; cerebral spinal ﬂuid; MRI; magnetic resonance imaging; CT; computerized tomogram; and VST; venous sinus thrombosis
Figure 1: Peripheral blood ﬁlm showing promyelocytes. The periph-
eral blood ﬁlm revealed frequent promyelocytes, most of them
with multiple Auer rods. Flow cytometric analysis conﬁrmed that
these cells were immature promyelocytes expressing CD45 (dim)
CD33 (dim), and CD13 and negative for CD34, HLADR, CD14,
CD15, CD64, and CD16. Additional FISH studies conﬁrmed the
presenceoft(15;17)PML-RARAfusionseeninacutepromyelocytic
leukemia.
Herein, we describe a case of ATRA-induced PC in a
middle-aged woman which occurred while she was recov-
ering from ATRA-based induction chemotherapy treatment
for APL. We also review the current literature and discuss the
managing principles of ATRA-induced PC.
2.CaseReport
A previously healthy, but obese 38-year-old Native American
female, sought surgical evaluation for a left ulnar nerve
entrapment syndrome. A routine preoperative laboratory
assessment demonstrated a hematocrit of 30%, WBC of 3 ×
109/L (48% lymphocytes, 6% monocytes, 16% segmented
polymorphonuclear cells, 25% promyelocytes, and 2%
blasts) and a platelet count of 13 × 109/L. Further blood test
including a coagulation panel showed normal electrolytes
and hepatic transaminases, mildly elevated serum lactate
dehydrogenase at 298U/L, prothrombin time of 14.5 sec-
onds (normal 11–13.5), partial thromboplastin time of 35
seconds (normal 25–34), ﬁbrinogen of 762mg/dL (normal,
212–470), thrombin time of 13 seconds (normal, 15–19),
and D-dimer 9.64μg/mL (normal, <0.40). Peripheral blood
ﬁlm showed several circulating blasts with coarse reddish-
purple granules and Auer rods in the cytoplasm, con-
voluted nuclei, prominent nucleoli and ﬁne open chro-
matin consistent with promyelocytes. Bone marrow biopsy
and aspirate revealed a hypercellular marrow dominated
by sheets of promyelocytic-appearing blasts. (Figure 1)
Immunohistochemical studies showed that the blasts were
positive for CD117 and myeloperoxidase, stained dimly for
CD45, and did not express HLA-DR. Cytogenetic analysis
demonstrated the characteristic t(15; 17) translocation and
FISH analysis conﬁrmed the presence of a PML/RARA
rearrangement. She began induction chemotherapy (idaru-
bicin 12mg/m2/day IV, days 1–3 and cytosine arabinoside
[Ara-C] 100mg/m2/day IV, days 1–7) in conjunction with
ATRA (45 mg/m2 daily in two divided doses PO). On
day 7, she was prescribed ﬂuconazole 400mg daily and
levoﬂoxacin 500mg daily for antifungal and antibacterial
prophylaxis, respectively. On day 17, she reported a throb-
bingandpersistentfrontalheadachewhichwasaccompanied
by photosensitivity, nausea, and vomiting. Her neurologic
exam was unremarkable. Ophthalmologic exam showed
bilateral papilledema but no retinal hemorrhages. A lumbar
puncture showed a CSF opening pressure of 300mm of
water (normal <200) with normal biochemical and cytologic
ﬁndings. Magnetic resonance imaging of the brain was
normal. ATRA was withheld and she received 1,000mg
of acetazolamide twice daily in conjunction with standard
antiemetics and analgesics. Over the course of the next week,
her neurologic and ocular symptoms improved, but they
did not completely resolve until 2 days after ﬂuconazole was
also discontinued. She has since completed consolidationCase Reports in Oncological Medicine 3
chemotherapy consisting of two cycles of arsenic trioxide
(0.15mg/kg/day, IV, 5 days/week for 5 weeks), followed by
two cycles of ATRA (45mg/m2/day in two divided doses,
PO, days 1–7) and daunorubicin (50mg/m2 IV, days 1–3)
without recrudescent neurologic symptoms [21]. She then
completed ATRA maintenance every other week for a year
in conjunction with daily 6-mercaptopurine and weekly
methotrexate [22]. She remains in clinical and molecular CR
at 18 months of followup.
3. Discussion
PC is a rare disorder with an annual incidence of approxi-
mately 1 case per 100,000 people, but predominantly aﬀects
obese women of childbearing age [23]. It manifests with
headache, nausea, and vomiting, as well as pulsatile tinnitus
and diplopia. If untreated, it can cause swelling of the optic
disc, which may lead to progressive optic atrophy and blind-
ness[24].ThoughtheexactetiologyofPCisnotclear,several
theories have been proposed such as increased production
of CSF, increased blood ﬂow to brain tissue, and increased
venous outﬂow resistance [25]. Several medical conditions
such as obstructive sleep apnea, pregnancy, Behcet’s disease,
and thyroid dysfunction have been implicated as risk factors
for PC. Also, a number of medications have been casually
associated with PC, including oral contraceptives, various
antibiotics, thyroid replacement, corticosteroid withdrawal,
and lithium [26–32]. Additionally, a strong link has been
identiﬁed with administration of growth hormones, tetra-
cycline and related compounds and vitamin A derivatives,
including ATRA [15, 20, 33–36].
It is unclear how ATRA causes PC. One hypothesis
suggests that retinoids enhance production of CSF and also
alter the lipid constituents of choroid plexus and arachnoid
villi, disrupting the normal transport systems and impeding
the absorption of CSF [37]. The maximum tolerated ATRA
dose in adults is 150mg/m2/day, and 45–60mg/m2/day for
c h i l d r e n ,b u tP Ch a so c c u r r e da tm u c hl o w e rd o s e si nb o t h
groups [13, 14, 38]. ATRA is oxidized by the cytochrome
P-450 system including isoforms CYP2C8, CYP2C9, and
CYP3A4. Concomitant administration of drugs that inhibit
or are metabolized by this system, most notably triazole
antifungals, can lead to toxic ATRA concentrations [39, 40].
To identify further cases of ATRA-induced PC, we
performed a systematic review of peer-reviewed publications
using Medical Subject Headings (MeSH), PubMed/Medline,
and Google Scholar databases. Keywords were used alone
and with the modiﬁers of “acute promyelocytic leukemia,”
“pseudotumor cerebri,” and “tretinoin”o r“ all-trans retinoic
acid.” We also examined the bibliographies of each relevant
article for additional references. Only publications in English
wereincorporatedinourreview.Includingourindexpatient,
we identiﬁed 21 case reports of PC occurring in patients who
received ATRA as a component of APL treatment [14, 19,
20, 38, 40–56]. We identiﬁed another 20 reports of ATRA-
induced PC in larger scale studies. The cohort size of these
studies ranged from 9 to 576 (median: 26) and included a
total of 763 patients [13, 55, 57–62]. Nevertheless, adequate
information regarding the patients’ clinical presentation and
outcome was available in only two instances [13, 62]. We,
therefore, accumulated and analyzed data from 23 cases
(Table 2).
The median age at diagnosis of PC was 27 years for
females(range:6to38years)and16yearsformales(range:4
to43years)withaslightlyhigherpreponderanceofincidence
among females (female to male ratio of 1.3:1). Data about
the role of body mass index (BMI), in ATRA-induced PC
was not readily available; only three case reports provided
information regarding patients’ BMI, which were reportedly
normal. As deﬁned by the Centers for Disease Control and
Prevention, our patient was obese (BMI 32) [63].
Neurologicsymptomswerereportedin22ofthepatients,
of whom all complained of headache, 11 (50%) had diplopia
(often with cranial nerve VI palsy), and 7 (32%) had
nausea and vomiting. Less common complaints that led
to a diagnosis of PC were blurred or distorted vision
(23%), photosensitivity (9%), tinnitus (5%), and convergent
strabismus (5%). Presenting signs of PC were described in
21 cases and included 5 (24%) with visual ﬁeld changes
such as blind spot enlargement and decreased visual acuity.
Papilledema was a uniform ﬁnding in the 21 cases in which
retinal exams were described.
The median time to the diagnosis of PC after beginning
of ATRA therapy was 14 days. (Range: 7 days to 10 months)
(Table 2) PC most often occurred during induction therapy
(n = 18, 78%) but also occurred during consolidation ther-
apy (n = 3, 13%) and during maintenance therapy (n = 8,
35%).
Strategies for treating PC were provided in all 23 cases.
For17patients(74%),ATRAwaswithheldsoonafterPCwas
recognized. ATRA was also withheld in three other cases but
only after other therapeutic interventions were ﬁrst imple-
mented. In 7 of the 20 cases (35%) where ATRA was held,
PC resolved with no further treatment. In the 13 other cases,
signs and symptoms resolved following therapeutic lumbar
punctures (5 of 13 cases, 38%) and the use of medications,
most notably diuretics—mannitol, glycerin, and acetazo-
lamide(11,85%);corticosteroids(4,31%);and/oranalgesics
(3, 23%). Neurologic symptoms resolved within a median
o fs e v e nd a y s( r a n g e :1 / 2d a yt o2 5w e e k s )a f t e rA T R Aw a s
discontinued.
In three cases, ATRA was continued despite the diagnosis
ofPC.Inoneinstance,thepatientwastreatedwithacetazola-
mide alone. Papilledema resolved within a month, although
he continued to have visual complaints at three months
followup. In the other two instances, individuals were
managed with high-volume therapeutic lumbar punctures;
neurologicsymptomsandincreasedcranialpressureresolved
within ﬁve and seven days, respectively. Including our index
patient, a total of eight patients (35%) were rechallenged
with ATRA after their neurologic condition improved. In
all but our index case, PC symptoms recurred after patients
were rechallenged with ATRA, yet in two of these cases
PC symptoms were suﬃciently mild that no therapeutic
intervention was required. CNS symptoms resolved in three
of the other ﬁve cases following acetazolamide use. ATRA
withdrawal and subsequent reintroduction at a reduced dose4 Case Reports in Oncological Medicine
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Table 3: Common drug interactions with tretinoin [39].
Drug(s) Interaction
Antiﬁbrinolytic agents (e.g., aminocaproic acid, aprotinin,
and tranexamic acid) May increase risk of thrombosis during tretinoin therapy.
Drugs that induce cytochrome P-450 system (e.g.,
barbiturates, carbamazepine, phenytoin, primidone,
rifabutin, and rifampin)
May decrease tretinoin concentrations and antineoplastic eﬃcacy.
Drugs that inhibit cytochrome P-450 (e.g., cimetidine,
erythromycin, ﬂuconazole, and ketoconazole)
May increase tretinoin concentrations and toxicity. Adjust tretinoin
concentrations when necessary.
Drugs that inhibit CYP-2C8 (e.g., atazanavir, gemﬁbrozil,
and ritonavir)
May increase tretinoin concentrations and toxicity. Adjust tretinoin
concentrations when necessary.
Estrogen-progestin oral contraceptives Tretinoin may decrease contraceptive eﬃcacy. The use of at least 1 other
eﬀective form of contraception during tretinoin therapy is recommended.
Progestin-only oral contraceptives Tretinoin may decrease contraceptive eﬃcacy. The use of at least 2 other
eﬀective forms of contraception during tretinoin therapy is recommended.
Tetracycline antibiotics (e.g., doxycycline, minocycline,
and tetracycline) May increase risk of PC.
Ethanol May increase CNS depression. Avoid concomitant use.
Hydroxyurea Synergistic antineoplastic eﬀects; may increase risk of cell lysis and potentially
fatal bone marrow necrosis.
St. John’s wort May decrease tretinoin concentrations and antineoplastic eﬃcacy. Avoid
concomitant use.
Vitamin A Increased risk of vitamin A toxicity. Avoid combination.
and prophylactic administration of acetazolamide prior to a
subsequent ATRA rechallenge are additional strategies that
clinicians have used in the context of PC treatment.
PC through inhibition of CYP enzymes and potenti-
ation of ATRA by triazole antifungals has been described
previously in only two instances [14, 56]. In retrospect, our
patient had multiple risk factors for PC. She was an obese
premenopausal female who received ATRA for treatment
of APL. In addition, she received highdoses of ﬂuconazole
for antifungal prophylaxis while she was receiving ATRA.
This may have played an important role in promoting PC
by increasing ATRA drug levels (Table 3). Of note, her
symptoms improved partially after we withheld ATRA but
did not resolve completely until 48 hours after ﬂuconazole
was also discontinued.
4. Conclusion
In summary, PC is a well-described syndrome which classi-
cally has been associated with obese women of childbearing
age. Although the pathogenesis is not well understood, it
has also been frequently reported in the context of ATRA
treatment for APL. In our literature survey, treatment of PC
most often included suspension of ATRA until neurologic
symptoms abated. For patients with PC whose neurologic
complaints do not improve after withholding ATRA, use of
acetazolamide, therapeutic high-volume lumbar punctures,
dexamethasone, and analgesics may be useful. Patients may
be rechallenged with ATRA once neurologic complaints
improve, but symptoms recur in most cases. Since ATRA is
an important component of all phases of APL treatment,
use of prophylactic acetazolamide prior to a subsequent
ATRA rechallenge may mitigate risk of recrudescent PC.
Drug interactions, including the one we highlight in this case
report between triazole antifungals such as ﬂuconazole and
ATRA, must also be kept in mind because ﬂuconazole is a
commonly used antifungal agent which is often employed
during treatment of acute leukemia.
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